02:02 , Aug 10, 2019 |  BioCentury  |  Product Development

Eat this, don't eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
23:17 , Aug 7, 2019 |  BC Extra  |  Politics & Policy

CMS broadens coverage of CAR T therapies

After receiving 146 comments across two comment periods, CMS has opened up its coverage criteria for CAR Ts. In a final National Coverage Determination issued Wednesday, the Centers for Medicare & Medicaid Services said it...
00:56 , Jul 31, 2019 |  BC Extra  |  Company News

July 30 Company Quick Takes: Gilead beats on revenues with the help of Biktarvy, Yescarta; plus Pfizer and Ligand

Biktarvy, Yescarta beat estimates  Gilead Sciences Inc. (NASDAQ:GILD) raised its 2019 sales guidance after reporting higher-than-expected 2Q19 earnings driven by sales of HIV drug Biktarvy bictegravir/emtricitabine/tenofovir alafenamide and CAR T therapy Yescarta axicabtagene ciloleucel. Biktarvy...
22:23 , Jul 24, 2019 |  BC Extra  |  Company News

Avalon seeks boost from GE cell therapy manufacturing tech

Avalon partnered with GE Healthcare to use its FlexFactory Cell Therapy platform to standardize, automate and accelerate the production of Avalon's cell therapies, including its lead candidate, a next generation CAR T therapy. While Avalon...
18:48 , Jun 27, 2019 |  BC Innovations  |  Distillery Therapeutics

4-1BBL fusion protein boosts T cell bispecific Abs for gastric cancer and lymphoma

DISEASE CATEGORY: Cancer INDICATION: Gastric cancer; lymphoma Tumor-targeted 4-1BBL fusion proteins could enhance the efficacy of T cell bispecific antibodies to treat gastric cancer and lymphoma. The fusion proteins consist of a trimer of the...
00:27 , Jun 22, 2019 |  BC Extra  |  Clinical News

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

Cotellic/Tecentriq combo misses in melanoma  Exelixis Inc. (NASDAQ:EXEL) revealed in a Thursday SEC filing that Cotellic cobimetinib plus Tecentriq atezolizumab from partner Genentech Inc. missed the primary endpoint of improving progression-free survival vs. Keytruda pembrolizumab...
22:01 , Jun 17, 2019 |  BC Extra  |  Financial News

Viela's $75M series B to support BLA, autoimmune pipeline

After attracting multiple crossover investors to its latest venture round, Viela’s $75 million series B could be the last private round for the MedImmune spinout. HBM Healthcare Investments led the financing with participation from fellow...
21:41 , Jun 13, 2019 |  BC Innovations  |  Emerging Company Profile

Gracell: Speeding up CAR T cells

With a platform that could reduce the manufacturing time of autologous CAR T cells from two weeks to one day, Gracell is lining up a set of therapies it could produce with the method. Gracell...
00:35 , Jun 13, 2019 |  BC Extra  |  Company News

Sobi buying Novimmune assets as it refocuses R&D

Less than a year after gaining an exclusive worldwide license for Gamifant emapalumab from Novimmune, Sobi is acquiring a newco formed around the hematology therapy for CHF515 million ($519.2 million) and restructuring its R&D pipeline...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...